Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most ...
Results from a small trial suggest a modified virus can instruct the immune system to wipe out disease-causing cells.
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both ...
U.S. Multiple Sclerosis Drugs Market to Reach USD 20.89 Billion and Europe USD 15.51 Billion by 2035 as Monoclonal Antibody ...
LONDON, Sept 1 (Reuters) - Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in ...
Novartis is taking social media by storm with a multiple sclerosis (MS) campaign that urges patients to #KnowYourMS, a ...
Wearable accelerometer-based real-life walking speed monitoring can track disability progression earlier and more often than ...
Novartis announced positive topline results from two Phase III trials evaluating remibrutinib in adults with relapsing ...
MRI brain network patterns differed in MS patients, with distinct changes linked to disability, cognition, and disease ...
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease that particularly affects young adults. The disease is ...
A large new U.S. study found that getting the recombinant zoster vaccine reduces the risk of shingles in adults with multiple ...
A personal reflection on living with multiple sclerosis, drawing parallels to the practice of hobbling horses, and finding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results